Circulating microRNAs (miRNA) in serum of patients with prostate cancer

Urology

Volumn 77, Issue 5, 2011, Pages 1265.e9-1265.e16

  Mahn, Robert ^a   Heukamp, Lukas C ^a   Rogenhofer, Sebastian ^a   Von Ruecker, Alexander ^a   Müller, Stefan C ^a   Ellinger, Jörg ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HPRT1 PROTEIN; MESSENGER RNA; MICRORNA; MIR 16; MIR 195; MIR 26A; MIR 32; MIR LET7I; RNU1A 1; SMALL NUCLEAR RNA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CANCER TISSUE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; RELIABILITY; RNA ISOLATION; SENSITIVITY AND SPECIFICITY; TISSUE LEVEL; TUMOR DIFFERENTIATION;

EID: 79955630404     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2011.01.020     Document Type: Article

References (28)

1. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320-1328.
2. Andriole GL, Grubb RL, III, Buys SS, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360:1310-1319.
3. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120:15-20. (Pubitemid 40094598)
4. Schmittgen TD. Regulation of microRNA processing in development, differentiation and cancer. J Cell Mol Med. 2008;12:1811-1819.
5. Bonci D, Coppola V, Musumeci M, et al. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med. 2008;14:1271-1277.
6. Dong Q, Meng P, Wang T, et al. MicroRNA let-7a inhibits proliferation of human prostate cancer cells in vitro and in vivo by targeting E2F2 and CCND2. PLoS ONE. 2010;5:e10147.
7. Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A. 2006;103:2257-2261. (Pubitemid 43271657)
8. Ambs S, Prueitt RL, Yi M, et al. Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res. 2008;68:6162-6170.
9. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435:834-838. (Pubitemid 40839735)
10. Ozen M, Creighton CJ, Ozdemir M, et al. Widespread deregulation of microRNA expression in human prostate cancer. Oncogene. 2008;27:1788-1793. (Pubitemid 351380263)
11. Porkka KP, Pfeiffer MJ, Waltering KK, et al. MicroRNA expression profiling in prostate cancer. Cancer Res. 2007;67:6130-6135. (Pubitemid 47037493)
12. Tong AW, Fulgham P, Jay C, et al. MicroRNA profile analysis of human prostate cancers. Cancer Gene Ther. 2009;16:206-216.
13. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105:10513-10518.
14. Brase JC, Johannes M, Schlomm T, et al. Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer. 2011;128:608-616.
15. Huang Z, Huang D, Ni S, et al. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer. 2010;127:118-126.
16. Resnick KE, Alder H, Hagan JP, et al. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol. 2009;112:55-59.
17. Tsujiura M, Ichikawa D, Komatsu S, et al. Circulating microRNAs in plasma of patients with gastric cancers. Br J Cancer. 2010;102:1174-1179.
18. Peltier HJ, Latham GJ. Normalization of microRNA expression levels in quantitative RT-PCR assays: identification of suitable reference RNA targets in normal and cancerous human solid tissues. rna. 2008;14:844-852.
19. Hunter MP, Ismail N, Zhang X, et al. Detection of microRNA expression in human peripheral blood microvesicles. PLoS ONE. 2008;3:e3694.
20. Heneghan HM, Miller N, Lowery AJ, et al. Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg. 2010;251:499-505.
21. Zhang HL, Yang LF, Zhu Y, et al. Serum miRNA-21: Elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy. Prostate. 2011;71:326-331.
22. Liang R, Bates DJ, Wang E. Epigenetic control of microRNA Expression and Aging. Curr Genomics. 2009;10:184-193.
23. Laterza OF, Lim L, Garrett-Engele PW, et al. Plasma microRNAs as sensitive and specific biomarkers of tissue injury. Clin Chem. 2009;55:1977-1983.
24. Wang JF, Yu ML, Yu G, et al. Serum miR-146a and miR-223 as potential new biomarkers for sepsis. Biochem Biophys Res Commun. 2010;394:184-188.
25. Schaefer A, Jung M, Miller K, et al. Suitable reference genes for relative quantification of miRNA expression in prostate cancer. Exp Mol Med. 2010;42:749-758.
26. Eskicorapci SY, Ozkara HA, Onder E, et al. Serum ribonuclease activity in the diagnosis of prostate cancer in men with serum prostate-specific antigen levels between 2.5 and 20 ng/mL. Clin Biochem. 2006;39:363-366.
27. Xi Y, Nakajima G, Gavin E, et al. Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. rna. 2007;13:1668-1674.
28. Grishok A. RNAi mechanisms in Caenorhabditis elegans. FEBS Lett. 2005;579:5932-5939. (Pubitemid 41484138)